Search Results - "Gouvea, Maria da Penha Gomes"
-
1
Anti-SARS-CoV-2 antibody immunoreactivity profiles during COVID-19 recurrence
Published in Revista da Sociedade Brasileira de Medicina Tropical (01-01-2022)“…BACKGROUNDThis study aimed to evaluate IgG and IgM levels in COVID-19 recurrence. METHODSThe serum antibody levels and clinical data from 73 healthcare workers…”
Get full text
Journal Article -
2
Clinical risk factors for predicting anti-Sars-CoV-2 antibody immunoreactivity duration after mild COVID-19 infection
Published in Revista brasileira de crescimento e desenvolvimento humano (2023)“…Introduction: coronavirus disease 2019 (COVID-19) is a complex multisystem disorder. It is not yet well known whether symptoms in the acute phase correlate…”
Get full text
Journal Article -
3
Previous biological therapy and impairment of the IFN-γ/IL-10 axis are associated with low immune response to 17DD-YF vaccination in patients with spondyloarthritis
Published in Vaccine (30-07-2022)“…Yellow fever (YF) vaccination is known to induce a suboptimal response in patients with autoimmune diseases (AIDs). To date, few studies have focused on the…”
Get full text
Journal Article -
4
The need for palliative care among patients with chronic diseases: a situational diagnosis in a university hospital
Published in Revista brasileira de geriatria e gerontologia (2019)“…Abstract Objective: To perform a situational diagnosis of a population hospitalized with chronic non-communicable diseases (NCD) who are potentially entitled…”
Get full text
Journal Article -
5
Hydroxychloroquine is associated with lower seroconversion upon 17DD-Yellow fever primovaccination in patients with primary Sjögren's syndrome
Published in Human vaccines & immunotherapeutics (31-12-2024)“…The present study aimed at investigating whether the hydroxychloroquine (HCQ) treatment would impact the neutralizing antibody production, viremia levels and…”
Get full text
Journal Article -
6
Serum biomarker profile orchestrating the seroconversion status of patients with autoimmune diseases upon planned primary 17DD Yellow fever vaccination
Published in Scientific reports (17-05-2021)“…The present study aimed to investigate whether the serum biomarkers of immune response orchestrate the seroconversion status in patients with autoimmune…”
Get full text
Journal Article -
7
Plaque Reduction Neutralization Test (PRNT) Accuracy in Evaluating Humoral Immune Response to SARS-CoV-2
Published in Diseases (01-01-2024)“…Massive vaccination positively impacted the SARS-CoV-2 pandemic, being a strategy to increase the titers of neutralizing antibodies (NAbs) in the population…”
Get full text
Journal Article -
8
Paulo Freire in the nursing academic production: a bibliometric study
Published in Revista de pesquisa, cuidado é fundamental (01-10-2017)“…Objective: To analyze the use of Paulo Freire's works in the nursing academic production, found in the LILACS/Brazil database, within the 2005 - 2015 period…”
Get full text
Journal Article -
9
EVENTOS ADVERSOS À 3ª DOSE DAS VACINAS ASTRAZENECA E PFIZER EM UMA COORTE DE TRABALHADORES DA SAÚDE
Published in The Brazilian journal of infectious diseases (01-10-2023)“…A vacina de vírus inativado CoronaVac (Sinovac/Butantan), e a ChAdOx1 (AstraZeneca/Fiocruz) em plataforma de vetor viral foram os principais imunizantes…”
Get full text
Journal Article -
10
CORRELAÇÃO CLÍNICA COM REATIVIDADE IMUNE APÓS INFECÇÃO LEVE A MODERADA POR COVID-19 EM UMA COORTE DE TRABALHADORES DA SAÚDE
Published in The Brazilian journal of infectious diseases (01-01-2022)“…Ainda não é completamente conhecido como a gravidade do quadro clínico da doença por coronavírus 2019 (COVID-19) se correlaciona com a resposta imune. O…”
Get full text
Journal Article -
11
Paulo Freire in the nursing academic production: a bibliometric study Paulo Freire na produção acadêmica de enfermagem: estudo bibliométrico
Published in Revista de pesquisa, cuidado é fundamental (31-10-2017)“…Objetivo: analisar a utilização das obras de Paulo Freire na produção científica de enfermagem, encontrada na base de dados LILACS/Brasil, no período de 2005 a…”
Get full text
Journal Article -
12
Timeline kinetics of protective immunity to SARS-CoV-2 upon primary vaccination and humoral response to variants after booster dose
Published in Vaccine (20-10-2023)“…New variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have emerged, imposing the need for periodic booster doses. However, whether…”
Get full text
Journal Article -
13
-
14
EVENTOS ADVERSOS À 3ª DOSE DAS VACINAS ASTRAZENECA E PFIZER EM UMA COORTE DE TRABALHADORES DA SAÚDE
Published in The Brazilian journal of infectious diseases (01-10-2023)Get full text
Journal Article -
15
Planned Yellow Fever Primary Vaccination Is Safe and Immunogenic in Patients With Autoimmune Diseases: A Prospective Non-interventional Study
Published in Frontiers in immunology (17-07-2020)“…Yellow Fever (YF) vaccination is suggested to induce a large number of adverse events (AE) and suboptimal responses in patients with autoimmune diseases (AID);…”
Get full text
Journal Article -
16
EFETIVIDADE, IMUNOGENICIDADE E SEGURANÇA DA MEIA DOSE DA VACINA CHADOX1 NCOV-19 CONTRA SARS-COV2 (PROJETO VIANA)
Published in The Brazilian journal of infectious diseases (01-01-2022)Get full text
Journal Article -
17
EVENTOS ADVERSOS ÀS VACINAS CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES DA SAÚDE
Published in The Brazilian journal of infectious diseases (01-01-2022)Get full text
Journal Article -
18
REATIVIDADE VACINAL E DURAÇÃO DE RESPOSTA IMUNE DA CORONAVAC E ASTRAZENECA EM UMA COORTE DE TRABALHADORES
Published in The Brazilian journal of infectious diseases (01-01-2022)Get full text
Journal Article -
19
REATOGENICIDADE COM MEIA DOSE DA VACINA CHADOX1 NCOV-19 (AZD1222)
Published in The Brazilian journal of infectious diseases (01-01-2022)Get full text
Journal Article -
20
Half dose ChAdOx1 nCoV-19 vaccine was equivalent to full doses to reduce moderate and severe COVID-19 cases
Published in IJID regions (01-12-2023)“…•In this study, we evaluated the effectiveness of half-dose (HD) ChAdOx1 nCoV-19 protocol.•A total of 29,469 participants who received a HD or full-dose (FD)…”
Get full text
Journal Article